SR46349-B, a 5-HT2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

Neuropsychopharmacology

Volumn 27, Issue 3, 2002, Pages 430-441

  Bonaccorso, Stefania ^a   Meltzer, Herbert Y ^a   Li, Zhu ^a   Dai, Jin ^a   Alboszta, Anna R ^a   Ichikawa, Junji ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT1A receptor agonism; 5 HT2A receptor antagonism; 5 HT2C receptor antagonism; Dopamine release; Haloperidol; Medial prefrontal cortex; Nucleus accumbens

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DOPAMINE; EPLIVANSERIN; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG SYNERGISM; FLUOROBENZENES; HALOPERIDOL; MALE; NUCLEUS ACCUMBENS; PHENOLS; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; TELENCEPHALON;

EID: 0036711059     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00311-1     Document Type: Article

References (64)

1. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathe J.M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn-Schmiedebergs Arch Pharmacol. 352:1995;374-385.
2. 1C receptors in rat brain. J Pharmacol Exp Ther. 255:1990;843-857.
3. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacol. 38:1999;1083-1152.
4. Bymaster F.P., Shannon H.E., Rasmussen K., DeLapp N.W., Ward J.S., Calligaro D.O., Mitch C.H., Whitesitt C., Ludvigsen T.S., Sheardown M., Swedberg M., Rasmussen T., Olesen P.H., Jeppesen L., Sayerberg P., Fink-Jensen A. Potential role of muscarinic receptors in schizophrenia. Life Sci. 64:1999;527-534.
5. 2 receptors. Abstracts of the III International Congress on Schizophrenia Research, Tucson, AZ
6. Davis K.L., Kahn R.S., Grant K., Davidson M. Dopamine in schizophrenia. a review and reconceptualization Am J Psychiat. 148:1991;1474-1486.
7. 2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem. 73:1999;1033-1042.
8. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 13:1993;350-356.
9. 2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function. a combined in vivo electrophysiological and microdialysis study Neurosci. 91:1999;587-597.
10. Di Giovanni G., Di Matteo V., Di Mascio M., Esposito E. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin2C/2B receptor agonists. a combined in vivo electrophysiological and microdialysis study Synapse. 35:2000;53-61.
11. 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacol. 38:1999;1195-1205.
12. 2C receptors Psychopharmacol. 150:2000;45-51. a.
13. 2C receptors. Brain Res. 865:2000;85-90. b.
14. 2C receptors in the control of central dopamine function. Trends Pharmacol Sci. 22:2001;229-232.
15. 2A receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacol. 38:1999;315-317.
16. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways. A combined dialysis and electrophysiological analysis in the rat Synapse. 36:2000;205-221.
17. Goff D.C., Amico E., Dreyfuss D., Ciraulo D. A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Am J Psychiat. 151:1995;429-431.
18. 11C]M100907. Synapse. 38:2000;421-431.
19. 2 adrenoceptor blockade. Science. 286:1999;105-107.
20. Hicks P.B., Browning J., Barwick S., Jones D., Wadenberg M.-L., Richter J.T., Young K.A. M100,907 acts both the nucleus accumbens and the prefrontal cortex to mediate the enhancement of the suppression of conditioned avoidance response by haloperidol. Schizophr Res. 36:1999;115.
21. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiat Clin Neurosci. 249(Suppl 4):1999;S90-S98. a.
22. 1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther. 291:1999;1227-1232. b.
23. 1A receptors on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 858:2000;252-263.
24. 1A receptor activation. a possible mechanism of atypical antipsychotic-induced cortical dopamine release J Neurochem. 76:2001;1521-1531. a.
25. 2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res. 907:2001;151-155. b.
26. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 26:2002;325-339.
27. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther. 277:1996;968-981.
28. Kuroki T., Meltzer H.Y., Ichikawa J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 288:1999;774-781.
29. Li X.-M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacol. 136:1998;153-161.
30. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. in press:2002.
31. 2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem. 74:2000;693-701.
32. 2C receptor subtypes and significance of the haloperidol dose used Neuropharmacol. 39:2000;1053-1063.
33. 2 receptor occupancy by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther. 265:1993;498-508.
34. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther. 251:1989;238-246.
35. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacol. 21:1999;106S-115S.
36. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 25:1999;233-255.
37. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacol. 37:1998;953-955.
38. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat. an in vivo microdialysis study J Neurochem. 54:1990;1755-1760.
39. 2 receptors in the rat brain. Neurosci. 54:1993;701-717.
40. Nomikos G.G., Iurlo M., Andersson J.L., Kimura K., Svensson T.H. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacol. 115:1994;147-156.
41. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
42. Pehek E.A. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse. 24:1996;12-18.
43. 2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res. 888:2001;51-59.
44. 2C receptor. J Pharmacol Exp Ther. 299:2001;83-89.
45. Rinaldi-Carmona M., Congy C., Santucci V., Simiand J., Gautret B., Neliat G., Labeeuw B., Le Fur G., Soubrie P., Breliere J.C. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-HT receptor antagonist. J Pharmacol Exp Ther. 262:1992;759-768.
46. 1A receptor activation contributes to ziprasidone-induced dopamine release in rat prefrontal cortex. Biol Psychiat. 48:2000;229-237.
47. 1C receptors. J Pharmacol Exp Ther. 260:1992;1361-1365.
48. 2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. Mol Psychiat. 5:2000;673-677.
49. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs. in vitro and in vivo receptor binding Psychopharmacol. 124:1996;57-73.
50. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Pro Natl Acad Sci. 86:1989;10156-10160.
51. Shipley J (1998): M100907 Phase IIB Trial. Presented at Hoechst Marion Roussel Conference on M100907, West Palm Beach Florida, April 1998
52. 2C receptors subtypes in the control of haloperidol-induced release of dopamine in the rat striatum. Soc Neurosci Abstr. 24(48.4):1998;108.
53. 2 receptors. J Pharmacol Exp Ther. 266:1993;1374-1384.
54. Tandon R. Cholinergic aspects of schizophrenia. Br J Psychiat. 174(Suppl 37):1999;7-11.
55. 2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacol. 148:2000;400-403.
56. 11C]raclopride? PET studies combined with microdialysis in conscious monkeys Brain Res. 841:1999;160-169.
57. 2A receptor antagonist MDL 100,907. Biol Psychiat. 44:1998;508-515.
58. 2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav. 68:2001;363-370.
59. 2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 299:2001;268-276.
60. Westerink B.H., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikstrom H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol. 412:2001;127-138.
61. Wiesel F.-A., Nordström A.-L., Farde L., Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacol. 114:1994;31-38.
62. 2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission. Brain Res Bull. 51:2000;75-81.
63. 2A receptor stimulation in rats pretreated with intermittent cocaine. Brain Res. 863:2000;254-258.
64. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., Bymaster F.P. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacol. 23:2000;250-262.